Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company pioneering T cell-engaging bispecific antibody therapies for solid tumors. This page serves as the definitive source for verified news and official updates about the company's innovative oncology pipeline, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated updates on key programs like CTIM-76 (targeting CLDN6+ cancers) and CT-95/CT-202 bispecific antibodies. All content is sourced directly from company filings and press releases, ensuring reliability for those monitoring developments in precision cancer immunotherapy.
Our news coverage focuses on three critical areas: Clinical Trial Advancements (Phase 1/2 updates, patient enrollment), Regulatory Progress (FDA communications, trial design approvals), and Strategic Collaborations (research partnerships, intellectual property developments). Each update is contextualized to show its significance within the broader oncology treatment landscape.
Bookmark this page for streamlined access to Context Therapeutics' latest developments in bispecific antibody research. Check back regularly for real-time updates on their mission to transform care for hormone-driven and treatment-resistant cancers.
Context Therapeutics (CNTX) announced a collaboration with Menarini Group to assess ONA-XR alongside elacestrant in metastatic breast cancer. The company reported a net loss of $4.0 million for Q2 2022, an improvement from $5.0 million in Q2 2021. Cash reserves stood at $42.9 million as of June 30, 2022, projected to sustain operations until Q4 2023. Notable pipeline advancements include ongoing Phase 2 trials with preliminary data anticipated in Q4 2022 and plans to initiate the ELONA trial by year-end.
Context Therapeutics (Nasdaq: CNTX) announced a collaboration with Menarini Group to support a Phase 1b/2 clinical trial of ONA-XR, an oral progesterone receptor antagonist, combined with elacestrant, a selective estrogen receptor degrader. Targeting ER+, PR+, HER2- metastatic breast cancer patients previously treated with a CDK4/6 inhibitor, this trial aims to explore enhanced tumor control through dual ER and PR blockade. Elacestrant showed a 30% reduction in progression risk compared to standard therapies. The trial is set to initiate in Q4 2022.
Context Therapeutics Inc. (Nasdaq: CNTX) reported its Q1 2022 financial results, revealing a net loss of $3.4 million compared to $0.9 million in Q1 2021. Cash and cash equivalents declined to $45.7 million from $49.7 million at year-end 2021. The company presented promising data from its ONA-XR clinical trial at the AACR Annual Meeting and has ongoing Phase 2 trials for breast, ovarian, and endometrial cancers. Preliminary data from these trials is expected later in 2022, alongside the selection of a candidate for the CLDN6xCD3 program.
Context Therapeutics Inc. (Nasdaq: CNTX) announced promising results from its Phase 2 trial of ONA-XR, a progesterone receptor antagonist, in treating advanced granulosa cell tumors. The results will be presented at the ASCO Annual Meeting scheduled for June 3-7, 2022. The study has progressed to evaluate ONA-XR in combination with the antiestrogen anastrozole. CEO Martin Lehr expressed optimism about ONA-XR's potential in targeting this rare ovarian cancer type. The abstract highlights significant activity of ONA-XR, marking a pivotal step in Context's clinical program for women's oncology therapies.
Context Therapeutics announced promising preclinical results for its lead candidate, ONA-XR, a progesterone receptor antagonist, at the AACR Annual Meeting 2022. The data showcases ONA-XR's potential in combination with standard therapies for hormone-positive tumors, demonstrating significant tumor regression in various preclinical models. Additionally, the company is progressing with its CLDN6xCD3 bispecific antibody program, aiming for candidate selection for IND-enabling studies by year-end. Preliminary data from ongoing Phase 2 trials is expected later this year.
Context Therapeutics announced that CEO Martin Lehr will participate in two virtual investor conferences in April 2022. The events include Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference on April 14 at 8:30 a.m. ET and the 21st Annual Needham Virtual Healthcare Conference on the same day at 2:15 p.m. ET. Context is focused on developing small molecule and immunotherapy treatments for breast and gynecological cancers, with its lead candidate ONA-XR undergoing multiple clinical trials.
Context Therapeutics (Nasdaq: CNTX) announced financial results for the year ending December 31, 2021, reporting a net loss of $10.5M compared to a net income of $6.6M in 2020. The company raised $28.75M from its IPO and $31.25M in a private placement, strengthening its cash position to $49.7M, sufficient to fund operations into 2024. Context highlighted positive preclinical data for its ONA-XR candidate and plans for upcoming Phase 2 clinical trial data. The company expects preliminary results from several trials in mid-2022 and aims to introduce a new bispecific antibody candidate for ovarian and endometrial cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) has announced that five abstracts will be presented at the AACR Annual Meeting 2022 from April 8-13 in New Orleans, LA. The company is focusing on its lead product candidate, onapristone extended release (ONA-XR), aimed at treating various hormone-driven female cancers. A webinar is scheduled for April 13, 2022, at 11 a.m. ET, where management will discuss these presentations and provide updates on ONA-XR's clinical program. Context has a robust clinical pipeline, including multiple ongoing trials for its promising therapies.
Context Therapeutics Inc. (Nasdaq: CNTX) announced that CEO Martin Lehr will present at the Sachs 15th Annual European Life Sciences CEO Forum on March 1-2, 2022, with on-demand viewing available. The company will also engage in one-on-one meetings from February 28 to March 4, 2022. Context focuses on developing small molecule and immunotherapy treatments for breast and gynecological cancers, particularly its lead candidate, ONA-XR, which is undergoing several clinical trials. For more details, visit their website.
Context Therapeutics announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D. as VP of R&D, effective January 5, 2022. These appointments come as the company approaches pivotal phases in its pipeline, particularly with its lead product candidate ONA-XR for treating women's cancers. The current Head of CMC, Bill Rencher, Ph.D., will transition to an advisory role. The new leadership team aims to advance research and development initiatives within the company, focusing on effective treatments for hormone-driven cancers.
